Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0
|
作者：
Venturella, Fabio [1 ]
Cancellieri, Giulia [1 ]
Giammanco, Marco [2 ]
Almerico, Anna Maria [1 ]
Aleo, Igor Daniele
Liga, Anastasia Valentina [1 ]
Mortillaro, Francesca [1 ]
Mistretta, Irene [1 ]
机构：
[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy
[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy
来源：
JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期
关键词：
cancer; lung; immuno-oncology; Nivolumab; SAFETY;
D O I：
10.4081/jbr.2023.11027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [2] A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
    Chen, Shuo
    Hu, Bin
    Li, Hui
    ONCOTARGETS AND THERAPY, 2018, 11 : 7691 - 7697
  • [3] Duration of nivolumab for pretreated, advanced non-small-cell lung cancer
    Geier, Margaux
    Descourt, Renaud
    Corre, Romain
    Leveiller, Guillaume
    Lamy, Regine
    Goarant, Eric
    Bizec, Jean-Louis
    Bernier, Cyril
    Quere, Gilles
    Amrane, Karim
    Gaye, Elisabeth
    Lucia, Francois
    Burte, Emilie
    Chouaid, Christos
    Robinet, Gilles
    CANCER MEDICINE, 2020, 9 (19): : 6923 - 6932
  • [4] Nivolumab after Progression to Platinum- Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Lopez Flores, M.
    Diz Tain, P.
    Delgado Sillero, I.
    Sanchez Cousido, L.
    Lopez Gonzalez, A.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Garcia Casabal, F.
    De Sande Gonzalez, L.
    Garcia Palomo, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1916 - S1917
  • [5] The safety of nivolumab for the treatment of advanced non-small cell lung cancer
    Metro, Giulio
    Ricciuti, Biagio
    Brambilla, Marta
    Baglivo, Sara
    Soli, Irene
    Minenza, Elisa
    Leonardi, Giulia Costanza
    D'arpino, Alessandro
    Colabrese, Daniela
    Tazza, Marco
    Zicari, Daniela
    Minotti, Vincenzo
    Chiari, Rita
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (01) : 101 - 109
  • [6] Nivolumab-refractory patients with advanced non-small-cell lung cancer
    Costantini, A.
    Fallet, V.
    Corny, J.
    Friard, S.
    Chouaid, C.
    Duchemann, B.
    Giroux-Leprieur, E.
    Taillade, L.
    Doucet, L.
    Brosseau, S.
    Wislez, M.
    Tredaniel, J.
    Cadranel, J.
    LUNG CANCER, 2019, 130 : 128 - 134
  • [7] Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer
    Basak, Edwin A.
    Koolen, Stijn L. W.
    Hurkmans, Daan P.
    Schreurs, Marco W. J.
    Bins, Sander
    Oomen-de Hoop, Esther
    Wijkhuijs, Annemarie J. M.
    den Besten, Ilse
    Sleijfer, Stefan
    Debets, Reno
    van der Veldt, Astrid A. M.
    Aerts, Joachim G. J., V
    Mathijssen, Ron H. J.
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 12 - 20
  • [8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [9] Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer
    Miyamoto, Shingo
    Nomura, Ryutaro
    Sato, Kengo
    Awano, Nobuyasu
    Kuse, Naoyuki
    Inomata, Minoru
    Izumo, Takehiro
    Terada, Yuriko
    Furuhata, Yoshiaki
    Bae, Yuan
    Kunitoh, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (02) : 160 - 164
  • [10] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
12345